Study Name:
Liberty N.O.T.U.S.

Targeted Disease(s):
COPD

Purpose of Study:

To evaluate the safety and efficacy of dupliumab in patients with moderate to severe COPD.

Study Dates:
June 1, 2020 - July 1, 2023

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Industry

ClinicalTrails.gov Identifier:
NCT04456673

Sponsor:
Sanofi

Trial URL:
COPDClinicalStudies.com

Register for Trial
Freedom From Smoking Clinic
, | Oct 25, 2021
Lung Mind Alliance Convening
, | Dec 08, 2021